Modern Slavery Statement
This statement is made pursuant to section 54(1) of the UK Modern Slavery Act 2015 and constitutes Science Group plc’s slavery and human trafficking statement for the financial year ending 31 December 2016.
Our business and supply chains
Science Group is a global provider of science, technology and product development consultancy services across a broad range of markets. Further information on Science Group’s businesses can be found at www.sciencegroup.com. All of Science Group’s employees are based in the UK or US.
Our supply chain consists of subcontractors for product development and advisory services, suppliers of scientific and engineering products, materials and services, facilities and maintenance contractors, and support and professional service providers. The majority of these suppliers are based in the UK, US and other low risk countries.
Our policies and procedures
Science Group has a zero tolerance approach to slavery and human trafficking of any kind within our businesses or supply chains. Our internal policies reflect our commitment to acting ethically and with integrity in all our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place. These include:
Due to the nature of our business and the locations and sectors in which we operate, the Board considers that there is a very low risk of slavery and human trafficking in our business and supply chains. However we will continue to review our approach and the effectiveness of our policies and procedures on an ongoing basis.
For and on behalf of the Board
Science Group plc
18 May 2017
About Science Group
Science Group offers independent advisory and leading-edge product development services focused on science and technology initiatives. Its specialist companies, Sagentia, Oakland Innovation, OTM Consulting and Leatherhead Food Research, collaborate closely with their clients in key vertical markets to deliver clear returns on technology and R&D investments.